Abstract
Some men affected with clinically localized prostate carcinoma suffer life-threatening recurrence, despite previous treatment with surgery or radiation therapy, underscoring the need for new, effective, systemic adjuvant treatment approaches. Recent molecular mechanism-based prostate cancer drug discovery efforts have identified several candidate targets for systemic prostate cancer adjuvant therapy; however, traditional cancer treatment development algorithms may not be appropriate for many of the new treatment strategies. To best exploit the clinical potential of these molecular treatment strategies, novel translational research strategies are required to support hypothesis-driven clinical research and development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
